

יולי 2024

Rivaroxaban Dexcel® 2.5, 10, 15, 20 mg, Film-coated Tablets

צוות רפואי נכבד,

חברת דקסל בע"מ שמחה להודיע על תחילת שיווק התכשיר החדש: ריברוקסבן דקסל 2.5, 10, 15, 20 מ"ג.

הרכב התכשירים:

Each film-coated tablet contains rivaroxaban 2.5, 5, 10 or 20 mg respectively.

התוויות מאושרות:

Rivaroxaban Dexcel 2.5 mg:

Rivaroxaban Dexcel 2.5 mg, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.

Rivaroxaban Dexcel 2.5 mg, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.

Rivaroxaban Dexcel 10 mg:

Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.

Prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), adults (following completion of at least 6 months therapy for DVT or PE).

Rivaroxaban Dexcel 15 mg:

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Paediatric population: Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Rivaroxaban Dexcel 20 mg:

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Paediatric population: Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

העלונים לצרכן נשלחו לפרסום במאגר התרופות שבאתר משרד הבריאות וניתן לקבלם מודפסים ע"י פנייה לבעל הרישום: דקסל בע"מ, רח' דקסל 1, אור עקיבא 3060000, ישראל, טל': 04-6364000.

ברכה,
דקסל בע"מ

